Helius Medical Technologies (NASDAQ:HSDT – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday, Zacks.com reports. The brokerage currently has a $2.25 price objective on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 12.50% from the company’s […]